HER2 News

News

Neoadjuvant SHR-A1811 Demonstrates Promise for Patients With HER2-Positive Breast Cancer

03/11/2025

Stephanie Holland

According to results from the phase 2 FASCINATE-N trial, neoadjuvant SHR-A1811 with or without pyrotinib demonstrated promising efficacy and safety among patients with HER2-positive breast cancer.

According to results from the...

03/11/2025

Oncology

News

Pertuzumab Retreatment Improves Survival for Patients With HER2-Positive Advanced Breast Cancer

02/27/2025

Stephanie Holland

According to updated results from the phase 3 PRECIOUS study, pertuzumab retreatment plus trastuzumab and physician’s choice chemotherapy improved survival among patients with HER2-positive, locally advanced or metastatic breast cancer.

According to updated results...

02/27/2025

Oncology

News

Trastuzumab Emtansine Improves Survival for Patients With HER2-Positive Early Breast Cancer

02/07/2025

Stephanie Holland

Updated results from the phase 3 KATHERINE trial demonstrated that trastuzumab emtansine improved survival among previously treated patients with HER2-positive early breast cancer.

Updated results from the phase 3...

02/07/2025

Oncology

News

First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

01/14/2025

Stephanie Holland

According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.

According to results from the...

01/14/2025

Oncology

Conference Coverage

Novel HER2-Directed Antibody Drug Conjugate Shows Promise in the Neoadjuvant Setting for HER2-Positive Breast Cancer

12/03/2024

Allison Casey

According to a phase 2 study, the novel HER2-directed antibody-drug conjugate SHR-A1811 showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.

According to a phase 2 study,...

12/03/2024

Oncology

FDA Alerts

FDA Approves Zanidatamab for Patients With Locally Advanced or Metastatic HER2-Positive Biliary Tract Cancer

11/21/2024

Stephanie Holland

Based on results from cohort 1 of the phase 2b HERIZON-BTC-01 trial, the US FDA has approved zanidatamab for patients with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who experience disease progression on or...

Based on results from cohort 1...

11/21/2024

Oncology

News

Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Advanced Colorectal Cancer

09/05/2024

Stephanie Holland

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.

According to results from the...

09/05/2024

Oncology

News

Trastuzumab Deruxtecan Shows Promise Among Patients With HER2-Expressing Unresectable or Recurrent Biliary Tract Cancer

08/14/2024

Stephanie Holland

According to results from a phase 2 study, trastuzumab deruxtecan demonstrated promising activity among patients with HER2-expressing unresectable or recurrent biliary tract cancer.

According to results from a...

08/14/2024

Oncology

News

SHR-A1811 Showed Promise Among Patients With HER2-Expressing Solid Tumors

07/25/2024

Stephanie Holland

According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.

According to results from a...

07/25/2024

Oncology

News

No Benefit from Addition of Atezolizumab to Standard of Care Among Patients With HER2-Positive Breast Cancer

12/08/2023

Allison Casey

According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.

According to results from a...

12/08/2023

Oncology

Recent News

News

Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer

04/15/2025

Stephanie Holland

According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.

According to results from the...

04/15/2025

Oncology

News

First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer

04/14/2025

Stephanie Holland

According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.

According to final efficacy and...

04/14/2025

Oncology

News

Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma

04/11/2025

Stephanie Holland

According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.

According to results from the...

04/11/2025

Oncology

News

Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma

04/11/2025

Emily Estrada

Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.

Plasma cytokines and chemokine...

04/11/2025

Oncology

News

The Potential of Targeting NRG1 for Esophageal Squamous Cell Carcinoma

04/10/2025

Allison Casey

Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.

Targeting NRG1 may present a...

04/10/2025

Oncology

News

First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%

04/09/2025

Stephanie Holland

According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.

According to 5-year follow-up...

04/09/2025

Oncology

News

Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL

04/09/2025

Emily Estrada

Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.

Treatment for...

04/09/2025

Oncology

News

Long-Term Real-World Efficacy of CPX-351 Therapy for Patients With High-Risk AML

04/09/2025

Emily Estrada

In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.

In a long-term, real-world...

04/09/2025

Oncology

FDA Approval

FDA Approves Nivolumab Plus Ipilimumab for Unresectable/Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

04/08/2025

Stephanie Holland

Based on results from the CHECKMATE-8HW trial, the FDA has approved nivolumab plus ipilimumab for patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal...

Based on results from the...

04/08/2025

Oncology

News

First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

04/08/2025

Stephanie Holland

According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...

According to long-term follow up...

04/08/2025

Oncology